Design and Validation of Plasma Proteins and Cytokine Panels to Identify Markers Associated With Response to Niraparib as Maintenance Treatment After First-line Platinum-based Regimen in Patients With Advanced Ovarian Cancer

NCT07059676 · clinicaltrials.gov ↗

NOT_YET_RECRUITING

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Advanced Ovarian Cancer

Interventions

DRUG: Zejula (Niraparib)

Sponsor

Clinica Universidad de Navarra, Universidad de Navarra